Where Monopar Therapeutics Stands With Analysts
Portfolio Pulse from Benzinga Insights
Monopar Therapeutics (NASDAQ:MNPR) has received 4 bullish analyst ratings in the last quarter, with an average 12-month price target of $15.0, a high of $24.00, and a low of $2.00. The current average price target remains unchanged from the previous average.
June 01, 2023 | 8:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Monopar Therapeutics has 4 bullish analyst ratings in the last quarter, with an average 12-month price target of $15.0.
The 4 bullish analyst ratings in the last quarter indicate a positive outlook for Monopar Therapeutics. The average 12-month price target of $15.0 suggests potential upside for the stock, which could lead to a short-term increase in its price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100